Literature DB >> 476438

Treatment of orthostatic hypotension with dihydroergotamine.

G Jennings, M Esler, R Holmes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 476438      PMCID： PMC1595691          DOI： 10.1136/bmj.2.6185.307

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  5 in total

1.  Central haemodynamic effects of dihydroergotamine in patients with orthostatic hypotension.

Authors:  I Nordenfelt; S Mellander
Journal:  Acta Med Scand       Date:  1972 Jan-Feb

2.  Haemodynamic effects of dihydroergotamine in patients with postural hypotension.

Authors:  S Bevegård; J Castenfors; L E Lindblad
Journal:  Acta Med Scand       Date:  1974-12

3.  Venoconstrictor effect of dihydroergotamine in superficial hand veins.

Authors:  W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

4.  Comparative effects of dihydroergotamine and noradrenaline on resistance, exchange and capacitance functions in the peripheral circulation.

Authors:  S Mellander; I Nordenfelt
Journal:  Clin Sci       Date:  1970-08       Impact factor: 6.124

5.  Pharmacological basis of the treatment of orthostatic disorders with ergot alkaloids.

Authors:  E Stürmer
Journal:  Cardiology       Date:  1976       Impact factor: 1.869
  5 in total
  10 in total

1.  An explanation of the unexpected efficacy of L-DOPS in pure autonomic failure.

Authors:  Murray Esler
Journal:  Clin Auton Res       Date:  2004-12       Impact factor: 4.435

2.  Treatment of postural hypotension with aerosol ergotamine.

Authors:  K Siminoski; C Lukinuk; P W Armstrong
Journal:  CMAJ       Date:  1988-07-01       Impact factor: 8.262

3.  Investigation of the venoconstrictor effect of 8' hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man.

Authors:  W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Pharmacological actions of the main metabolites of dihydroergotamine.

Authors:  E Müller-Schweinitzer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Low bioavailability as a cause of apparent failure of dihydroergotamine in orthostatic hypotension.

Authors:  I N Olver; G L Jennings; A Bobik; M Esler
Journal:  Br Med J       Date:  1980-07-26

Review 6.  Treatment of postural hypotension. A review.

Authors:  R A Ahmad; R D Watson
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

7.  Bioavailability of dihydroergotamine in man.

Authors:  P J Little; G L Jennings; H Skews; A Bobik
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

8.  Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects.

Authors:  P A Wyss; J Rosenthaler; E Nüesch; W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 9.  Chronic hypotension.

Authors:  I B Davies
Journal:  J R Soc Med       Date:  1982-08       Impact factor: 18.000

10.  Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure.

Authors:  Amy C Arnold; Claudia E Ramirez; Leena Choi; Luis E Okamoto; Alfredo Gamboa; André Diedrich; Satish R Raj; David Robertson; Italo Biaggioni; Cyndya A Shibao
Journal:  Front Physiol       Date:  2014-07-24       Impact factor: 4.566
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.